The Ocular Epidemiology Research Group, led by Prof Cheng Ching-Yu, aims to develop and facilitate collaborative and translational research by integrating big data, omics, and machine learning analytics into large scale population-based studies. The strategic goal of our group is to improve the eye health of populations in Singapore and globally, and to become one of the leading international centres for population science and digital health of eye diseases by:
Our Vision
Our Aims
The Ocular Epidemiology Research Group brings together innovative population health research and cutting-edge technology, such as a next-generation sequencing and artificial intelligence, with a focus on our theme-oriented strategy. Our group has multi-disciplinary expertise in all aspects of clinical and epidemiological research. We mainly research and develop the following areas:
Cohort |
Age range |
Ethnicity |
Number |
Data Collected |
Singapore Malay Eye Study (SiMES) | 40-80 years | Malays | 3280 | Prevalence, risk factors, and impact of visual impairment and major eye diseases in Singaporean Malays |
Singapore Indian Eye Study (SINDI) | 40-80 years | Indians | 3400 | Prevalence, risk factors, and impact of visual impairment and major eye diseases in Singaporean Indians |
Singapore Chinese Eye Study (SCES) | 40-80 years | Chinese | 3353 | Prevalence, risk factors, and impact of visual impairment and major eye diseases in Singaporean Chinese |
The Singapore Prospective Study Programme (SP2) Ancillary study | 24-95 years | Chinese, Malays and Indians | 5000 | Prevalence, environmental and genetic risk factors, and impacts of cardiovascular and metabolic diseases (e.g., hypertension, dyslipidemia, obesity, and diabetes mellitus) |
Polyclinic Study | 50+ years | Chinese | 2000 | Ocular and image biomarkers for glaucoma |
Cohort Highlights
The SEED study is a multi-ethnic longitudinal population-based study, comprised of over 10,000 adult participants aged 40 years or older in Singapore. It included three large population-based studies: the Singapore Malay Eye Study (SiMES), the Singapore Indian Eye Study (SINDI), and the Singapore Chinese Eye Study (SCES), with a focus on studying major eye diseases, including diabetic retinopathy, age-related macular degeneration, glaucoma, refractive errors and cataract. As one of the largest epidemiological databases and biobanks for eye diseases globally, SEED data has been widely used by national and international agencies to help guide public policy decisions on screening and early detection of age-related eye diseases. Furthermore, SEED findings have also contributed to other epidemiological areas such as machine/deep learning and genetic discoveries. More detailed information regarding SEED study can be found here.
The Asian Eye Epidemiology Consortium (AEEC) is a collaborative network of population-based studies performed across Asia with the overall aim of developing large datasets to provide deeper insights on the trends and associated risk factors of major age-related eye diseases among Asians. The AEEC network consist of over 40 population-based studies originating from at least 10 different Asian countries. Currently, data from the AEEC network has provided key insights into major age-related eye diseases in Asians, such as geographic atrophy, primary open-angle glaucoma, myopia, and diabetic retinopathy. We welcome new population studies to join the consortium.
Project |
Principal Investigator | Period |
Characterising the Role of Iris Surface Features in Iris Sponginess and their Relevance to Angle-closure Glaucoma | Prof Cheng Ching-Yu | 2016 - 2021 |
Deep Phenotyping and Genetic Landscaping of Primary Open Angle Glaucoma | Prof Cheng Ching-Yu | 2017 - 2022 |
Diabetes Study on Nephropathy and Other Microvascular Complications (DYNAMO): Retinal Microvasculature as a Window to Study Mechanisms and Pathways in Diabetic Nephropathy | Prof Wong Tien Yin | 2017 - 2022 |
The Singapore Epidemiology of Eye Diseases (SEED) Study 3: Prospective Multi-ethnic Cohort Study of 12-year Incidence, Risk factors, and Impact of Major Age-related Eye Diseases | Prof Cheng Ching-Yu | 2018 - 2022 |
Translational Asian Age-related Macular Degeneration Programme (TAAP): Population Health: Characterising Disease Burden, Novel and Genetic Risk Factors in Asians | Prof Cheng Ching-Yu & Prof Wong Tien Yin | 2018 - 2023 |
Artificial Intelligence Programme in Diabetic Retinopathy and Complications | Prof Wong Tien Yin | 2019 - 2021 |
Artificial Intelligence for Functional VIsion Screening Using Retinal Imaging (AVIRI) |
Dr Tham Yih Chung |
2019 - 2021 |
Community-based Screening for Pathological Visual Impairment among Elderly Residents using Artificial-Intelligence Integrated Retinal Imaging |
Dr Tham Yih Chung |
2019 - 2022 |
COVID-19 Pandemic: Triaging of ‘Only Urgent Eye Referrals’ from Polyclinics (TOP) using Retinal Photograph-based Deep Learning | Dr Tham Yih Chung | 2020 - 2021 |
From Machine to Machine-developing a Deep Learning Algorithm for Quantification of Ocular Traits based on Retinal Photographs |
Dr Tyler Hyungtaek Rim |
2020 - 2021 |
Implementation of Community-based Elderly Health Care for Eye and Systemic Diseases Using Automated Screening |
Dr Tyler Hyungtaek Rim |
2020 - 2022 |
SERI-based Machine Learning and AI Talent (SMAT) Programme |
Dr Tyler Hyungtaek Rim |
2019 - 2021 |
The Retina as a Window to Vascular and Neurological Disorders |
Prof Wong Tien Yin |
2021 - 2022 |
Digital and Precision Community Screening Platform for Ageing Diseases: Vision, Metabolism and Heart |
Prof Cheng Ching-Yu |
2021 - 2025 |
Project Highlights
Visual impairment is a major public health problem, associated with reduced quality of life and increased risk of frailty and mortality. Globally in 2020, an estimated 553 million people had visual impairment and 43 million were blind. 40% of visual impairment is related to refractive error that requires the provision of spectacles in community settings; however, the remaining 60% of cases cannot be corrected with spectacles and require assessment, diagnosis, treatment, and possibly surgery in eye-care settings led by ophthalmologists. These 60% of people with visual impairment can be referred to as having disease-related visual impairment (i.e., substantial loss of vision caused by an eye disease, and unrelated to refractive error). If detected early, these conditions can be treated, thus preventing or slowing development of vision loss. We developed a single-modality, retinal photograph-based deep learning algorithm (termed AVIRI) to detect disease-related visual impairment, using a total of 15,175 eyes from a multi-ethnic Asian population-based eye study. We also did independent validation of the algorithm using datasets of eyes from three other population-based studies and two clinic-based studies (total of 16,963 eyes), which generally showed that the algorithm had optimal performance. This is the first study to show the use of a single-modality deep learning algorithm, using only a single macular-centred retinal photograph, for identification. The unique design of this algorithm enables it to potentially be used as an efficient automated referral tool in community screening. Moving forward, there are plans to perform real-world validation to enable translation of this innovation for community screening use. Our work was published in Lancet Digital Health and was featured as Editor’s pick. More details can be found here.
Cardiovascular disease is the leading cause of death worldwide. The retina is the only organ that allows direct, non-invasive, in-vivo visualisation of the microvasculature and neural tissues. In recent decades, our understanding of retina-systemic relationships has relied on classic epidemiological studies based on observable, human-defined retinal features (e.g., retinopathy or retinal vascular calibre). The potential discovery of unobservable retinal features associated with systemic diseases has been enhanced by advances in artificial intelligence technology, specifically deep learning. Coronary artery calcium (CAC) is a preclinical marker of atherosclerosis and is strongly associated with risk of clinical cardiovascular disease. We have extended this concept of retina-systemic relationships and hypothesise that retinal photograph-based deep learning can also predict CAC score, and this retinal-predicted score (termed “RetiCAC) can also be used as a risk stratification tool for cardiovascular events. In our study, similar to the current CT-measured CAC stratification system, the relative risk of cardiovascular disease events showed a dose-response association across the three risk strata. Overall, the proposed new stratification system based on RetiCAC score showed comparable performance in predicting cardiovascular disease events compared with conventional CT-measured CAC score. Thus, retinal photography could potentially be adopted as a relatively simple and non-radiation imaging modality for cardiovascular disease risk classification. Our work was published in Lancet Digital Health.
Chronic kidney disease (CKD) is a major health condition associated with significant morbidity, cardiovascular disease and mortality. Screening for CKD is challenging in community and primary care settings, even in high-income countries because of the need to obtain serum levels of creatinine, or testing urine for protein. The retina being accessible to non-invasive imaging and retinal changes have been shown to provide information on systemic vascular and metabolic diseases, we developed an artificial intelligence deep learning algorithm (DLA) to detect CKD from retinal images, which may add to existing CKD screening strategies. We developed and validated the DLA utilising retinal images and data from the Singapore Epidemiology of Eye Diseases (SEED) and externally validated the DLA in two independent datasets in Singapore (SP2) and China (BES). We developed an ‘Image-only’ model based on macula-centred images from both eyes. For comparison, we also developed a ‘Risk-factor’ model based on key risk factors including age, sex, ethnicity, diabetes and hypertension. The image-only DLA showed an AUC of 0.911 in internal validation and 0.733 and 0.835 in external tests sets. Corresponding estimates for the risk-factor model were 0.916, 0.829 and 0.887. The image-only DLA and risk factor DLAs achieve high AUCs in SEED internal validation and modest to good AUCs in external test sets. Our findings show that for CKD detection, a retinal-image only DLA is similar to information from a classic risk-factor model and support the potential of a retinal-imaged based DLA to be adopted for first stage CKD screening before confirmation by serum creatinine. Our work was published in Lancet Digital Health. More details can be found here.
We have established Singapore as a leading hub of ophthalmic epidemiology, clinical and genetic research in Asia with a particular focus on diseases that are prevalent in this region. Data collected from our group has been used widely by national and international agencies (e.g. the Ministry of Health (MOH) Singapore, the World Health Organization, the Global Burden of Disease programme, etc.) and clinical guidelines (e.g. 2014 MOH Diabetes Guidelines, 2016 Asia Pacific Glaucoma Guidelines, 2016 American Diabetes Association Guidelines, 2017 International Council of Ophthalmology Diabetic Eye Care Guidelines). The data has been used to provide estimates of eye disease burden to set up the national DR screening. It also assists both the MOH’s planning for healthcare manpower (future ophthalmology and optometry manpower) and the College of Ophthalmology’s planning for the National Ophthalmology Road Map 2030 plan in Singapore.
In addition, we also provide research expertise, resource, and consultation for other research centres, hospitals and ophthalmic institutions in Singapore and Asia. We conduct training programmes for clinicians, research fellows and graduate students interested in big data analytics, digital health, and ophthalmic epidemiology.
The list below is selected from more than 600 publications.
Head
Prof Cheng Ching-Yu
Deputy Head
Assoc Prof Charumathi Sabanayagam
Investigators & Fellows
Research Associate / Officer
Data Science Team
Research Clinic Team
Biobank Laboratory
Research Administration
SNEC Clinical Team
SERI Research Team